Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
AstraZeneca
Age
30–50
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Provision of a written informed consent
Men or women who are 30 to 80 years of age
Female patients: postmenopausal or surgically sterile
Diagnosed with type 2 diabetes with C-peptide levels \> 0.8 ng/mL
Treated with diet alone or treatment with a single oral antidiabetic agent or low doses of two oral antidiabetic agents
You may not be if
Type 1 diabetes
New York Heart Association heart failure Class III or IV
Treatment with chronic insulin
History of hypersensitivity or intolerance to any peroxisome proliferator-activated receptor agonist (like Actos or Avandia), or to other PPAR g or PPAR a and g agonists.
History of drug-induced myopathy or drug-induced creatine kinase elevation, liver enzyme elevations, neutropenia (low white blood cells)
Creatinine levels above 1.2 mg/dL
Received any investigational product in other clinical studies within 30 days
Any clinically significant abnormality identified on physical examination, laboratory tests or electrocardiogram, which in the judgment of the investigator would compromise the patient's safety or successful participation in the clinical study
